REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
Semantic ScholarReview

Assessment of mitochondrial peptide humanin in women with polycystic ovary syndrome: Serum and skeletal muscle profile

Kutuk Irem Sonmezoglu, Senay Akı, Ali Haydar Demirel, S. Mumuşoğlu, T. Çiftçi, B. Yildiz
Endocrine Abstracts2024DOI: 10.1530/endoabs.99.oc13.2

Citations

0

Subjects

Non-Human

Study Context

Review papers consolidate the current state of knowledge on a topic. While they don't present new experimental data, they offer valuable context and identify gaps in existing research.

Why This Matters

This research contributes to the growing body of evidence on humanin. Understanding the mechanisms and clinical applications of these peptides is an active area of investigation.

Citation

Kutuk Irem Sonmezoglu, Senay Akı, Ali Haydar Demirel et al.. (2024). Assessment of mitochondrial peptide humanin in women with polycystic ovary syndrome: Serum and skeletal muscle profile. Endocrine Abstracts. https://doi.org/10.1530/endoabs.99.oc13.2

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.